These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 8656271)
101. Melanomas and other skin neoplasms. Chemotherapy and new treatments. Rümke P Curr Opin Oncol; 1990 Apr; 2(2):397-406. PubMed ID: 2095251 [No Abstract] [Full Text] [Related]
102. Treatment of tufted angioma with interferon alfa: role of bFGF. Robenzadeh A; Don PC; Weinberg JM Pediatr Dermatol; 1998; 15(6):482. PubMed ID: 9875976 [No Abstract] [Full Text] [Related]
103. Neonatal dermal hematopoiesis associated with diffuse neonatal hemangiomatosis. Evole-Buselli M; Hernandez-Marti MJ; Gascó-Lacalle B; Esquembre Menor C; Mascuñan-Diaz I; Sorni-Valls G Pediatr Dermatol; 1997; 14(5):383-6. PubMed ID: 9336812 [TBL] [Abstract][Full Text] [Related]
104. Adjuvant therapy of high-risk malignant melanoma patients with gamma interferon. Landthaler M; Braun-Falco O J Am Acad Dermatol; 1989 Apr; 20(4):687-8. PubMed ID: 2497156 [No Abstract] [Full Text] [Related]
105. Spiegler-Fendt type lymphocytoma cutis: a case report of two patients successfully treated with interferon alpha-2b. Hervonen K; Lehtinen T; Vaalasti A Acta Derm Venereol; 1999 May; 79(3):241-2. PubMed ID: 10384934 [No Abstract] [Full Text] [Related]
106. [Roferon: present and future indications]. Ostronoff M; Zambon E; Schlumberger M; Parmentier C; Hayat M Bull Cancer; 1990; 77(12):1245-9. PubMed ID: 1981981 [No Abstract] [Full Text] [Related]
113. Broader Options for Experimental Clinical Research in Melanoma - Time for Adaptive Platform Trials? Trikalinos TA NEJM Evid; 2024 Oct; 3(10):EVIDe2400284. PubMed ID: 39315868 [No Abstract] [Full Text] [Related]
114. The prognostic index in malignant melanoma. Kopf AW JAMA; 1978 Jun; 239(25):2695. PubMed ID: 650848 [No Abstract] [Full Text] [Related]
115. A randomized trial of interferon-alpha in cervical dysplasia. Gostout BS; Hartmann LC; Suman VJ; Fay NE; Jefferies JA; Morton RF; Gaffey TA; Farr GH; Tschetter LK; Abu-Ghazaleh S; Gallenberg MM; Hatfield AK Int J Gynaecol Obstet; 2001 Aug; 74(2):207-10. PubMed ID: 11502303 [No Abstract] [Full Text] [Related]
116. [Melanoma and Non-Melanoma Skin Cancers]. Uhara H Gan To Kagaku Ryoho; 2024 Apr; 51(4):392. PubMed ID: 38644303 [No Abstract] [Full Text] [Related]
117. Adjuvant Therapy in the Treatment of Melanoma. Bello DM; Ariyan CE Ann Surg Oncol; 2018 Jul; 25(7):1807-1813. PubMed ID: 29468608 [No Abstract] [Full Text] [Related]
118. ASO Author Reflections: What Role Do Surgeons Play in the Era of Effective Systemic Therapy for Melanoma? Nelson DW; Faries MB Ann Surg Oncol; 2019 Dec; 26(13):4619-4620. PubMed ID: 31531796 [No Abstract] [Full Text] [Related]
119. Cost-Effective Patient Selection for Adjuvant Therapy in Stage IIIA Melanoma. Sondak VK; Messina JL; Tarhini AA J Am Coll Surg; 2020 Nov; 231(5):554-556. PubMed ID: 33491653 [No Abstract] [Full Text] [Related]
120. Immunotherapy in the adjuvant setting for high-risk melanoma. Weber JS Clin Adv Hematol Oncol; 2018 Aug; 16(8):546-548. PubMed ID: 30148825 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]